economical value of vaccines for the developing countries—the case of instituto butantan, a public institution in brazil经济价值的疫苗对发展中国家(instituto butantan案例在巴西一个公共机构.pdfVIP

Policy Platform Economical Value of Vaccines for the Developing Countries—The Case of Instituto Butantan, a Public Institution in Brazil 1,2 1 1 1 Paulo Lee Ho , Eliane Namie Miyaji , Maria Leonor Sarno Oliveira , Waldely de Oliveira Dias , Flavia 1 1 ´ 1 1,2 Saldanha Kubrusly , Martha Massako Tanizaki , Elizabeth Angelica Leme Martins , Isaias Raw * ˜ ˜ ˜ 1 Instituto Butantan, Sao Paulo, SP, Brazil, 2 Fundac¸ao Butantan, Sao Paulo, SP, Brazil Introduction these institutions maintained scientific about 25,000 health care centers, fulfilling research programs but had limited capa- a fundamental role of the SUS. A recent review has discussed the bility for meeting good manufacturing The situation in Brazil contrasts with economic value of vaccine for developed practices (GMPs) in vaccine production. that of other developing countries. In countries. The situation is quite different The implementation of the MH policy of India, private for-profit companies have in developing countries, and we examine local procurement required substantial emerged as the major vaccine producers. the situation in Brazil. Vaccines are of investments to upgrade the production In Chi